Germany - Drugs

Description

The purpose of this notice is to conclude agreements with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book V (SGB V). The invitation to participate is addressed only to pharmaceutical companies or associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act. This is not an open procedure pursuant to Section 15 VgVi. V. m. § 119 para. 3 GWB, but a publication of the invitation to conclude/join rebate contracts with fixed and non-negotiable conditions for all participants, including the amount of the rebate. An unlimited number of pharmaceutical companies or associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act may become contracting parties.
This notice serves to conclude agreements on the active ingredient "4-hydroxybutanoic acid (ATC-CODE: N07XX04)" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (discount agreements). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Abacavir (ATC-CODE: J05AF06) pharmaceutical form: FTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Acemetacin (ATC-CODE: M01AB11) Dosage form: HKP" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (discount contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Albendazole (ATC-CODE: P02CA03)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is March 5, 2025. In any case, the contracts will end on April 30, 2025. This announcement serves to conclude agreements on the active ingredient "Amiloride, hydrochlorothiazide (ATC-CODE: C03EA01) pharmaceutical form: TAB" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Amlodipine, Bisoprolol (ATC-CODE: C07FB07) Dosage form: TAB" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is March 5, 2025. In any case, the contracts will end on April 30, 2025. This announcement serves to conclude agreements on the active ingredient "Amlodipine, Candesartan (ATC-CODE: C09DB07) Dosage form: FTA" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "amlodipine, hydrochlorothiazide, ramipril (ATC-CODE: C09BX03)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is March 5, 2025. In any case, the contracts will end on April 30, 2025. This announcement serves to conclude agreements on the active ingredient "Bezafibrate (ATC-CODE: C10AB02) Dosage form: FTA, UTA" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Brinzolamid, Brimonidin (ATC-CODE: S01EC54)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Brivudine (ATC-CODE: J05AB15) Dosage form: TAB" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. This announcement serves to conclude agreements on the active ingredient "Cefpodoxime (ATC-CODE: J01DD13) Dosage form: GSE, PSE, SAF, TSA" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (discount contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. This announcement serves to conclude agreements on the active ingredient "Chlorprothixen (ATC-CODE: N05AF03) Dosage form: FTA, UTA" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Clomipramine (ATC-CODE: N06AA04) Dosage form: FTA, TAB, UTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (discount contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail or b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs have been received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is March 5, 2025. In any case, the contracts will end on April 30, 2025. This announcement serves to conclude agreements on the active ingredient "Colestyramine (ATC-CODE: C10AC01) Dosage form: GSE, PSE, PUL" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Desmopressin (ATC-CODE: H01BA02) Dosage form: LOE, NAS" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Diazepam (ATC-CODE: N05BA01) Dosage form: TAB" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs have been received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Efavirenz (ATC-CODE: J05AG03) Dosage form: FTA" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs have been received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "ferric carboxymaltose (ATC-CODE: B03AC)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs have been received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Fluorouracil, salicylic acid (ATC-CODE: L01BC52)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs have been received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Fluticasone, Salmeterol (ATC-CODE: R03AK06) Dosage form: DOS, IHP" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs have been received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Glycerol trinitrate (ATC-CODE: C01DA02) Dosage form: LOE, SPR" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Ibandronic acid (ATC-CODE: M05BA06) pharmaceutical form: ARR" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is March 5, 2025. In any case, the contracts will end on April 30, 2025. This announcement serves to conclude agreements on the active ingredient "leuprorelin acetate (ATC-CODE: L02AE02)" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is March 5, 2025. In any case, the contracts will end on April 30, 2025. This announcement serves to conclude agreements on the active ingredient "Levocetirizine - available only on prescription (ATC-CODE: R06AE09) Pharmaceutical form: FTA" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Solutions for parenteral nutrition Combinations ATC code B05BA10 (ATC-CODE: B05BA10)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (discount contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Lovastatin (ATC-CODE: C10AA02) Dosage form: TAB" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Macrogol (drug only) (ATC code: A06AD65)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "memantine (ATC code: N06DX01) pharmaceutical form: LSE" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Midazolam (ATC code: N05CD08)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (discount agreements). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is March 5, 2025. In any case, the contracts will end on April 30, 2025. This announcement serves to conclude agreements on the active ingredient "Minocycline (ATC code: J01AA08) Dosage form: FTA, HKP, KAP" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Moxifloxacin (ATC code: J01MA14) pharmaceutical form: FTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs have been received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Naltrexone (ATC code: N07BB04) pharmaceutical form: FTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs have been received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is March 5, 2025. In any case, the contracts will end on April 30, 2025. This announcement serves to conclude agreements on the active ingredient "Nevirapine (ATC code: J05AG01) Dosage form: TAB" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Security Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs have been received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Nitrofurantoin (ATC code: J01XE01) pharmaceutical form: KAP, TAB, UTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs have been received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "norfloxacin (ATC code: J01MA06) pharmaceutical form: FTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs have been received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Ofloxacin (ATC code: J01MA01) pharmaceutical form: FTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Oseltamivir (ATC code: J05AH02)" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "peginterferon beta-1-a (ATC code: L03AB13)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is March 5, 2025. In any case, the contracts will end on April 30, 2025. This announcement serves to conclude agreements on the active ingredient "Pentoxifylline (ATC code: C04AD03) pharmaceutical form: RED, REK, RET, sustained-release film-coated tablets" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (discount contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is March 5, 2025. In any case, the contracts will end on April 30, 2025. This announcement serves to conclude agreements on the active ingredient "Piretanide (ATC code: C03CA03) dosage form: TAB" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Pyridostigmine bromide (ATC code: N07AA02) Dosage form: TAB, UTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is March 5, 2025. In any case, the contracts will end on April 30, 2025. This announcement serves to conclude agreements on the active ingredient "Quinapril, HCT (ATC code: C09BA06) pharmaceutical form: FTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is March 5, 2025. In any case, the contracts will end on April 30, 2025. This announcement serves to conclude agreements on the active ingredient "Ramipril, Piretanide (ATC code: C09BA05) Dosage form: TAB" with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Tamoxifen (ATC code: L02BA01) Dosage form: FTA, TAB" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (discount contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Triamcinolon-Depot (ATC code: H02AB08)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Voriconazole (ATC code: J02AC03) pharmaceutical form: PIF, PSE" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Zuclopenthixol (ATC code: N05AF05) pharmaceutical form: FTA" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The closing date for receipt of accessions is 05.03.2025. In any case, the contracts will end on 30.04.2025. The purpose of this announcement is to conclude agreements on the active ingredient "Zuclopenthixol (ATC code: N05AF05) pharmaceutical form: ILO" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Book Five (SGB V) (rebate contracts). Pursuant to Section 130a (8) Sentence 1 SGB V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. The corresponding information under IV.1.1) is only due to the systematics of this form. An unlimited number of pharmaceutical companies or employee associations of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The information under II.2.5) is owed to the systematics of this publication form. The conclusion of the contract or an accession takes place by sending the required completed self-declarations or proofs as well as the contract(s) either:a) Signed by hand (written form according to § 126 BGB) by mail orb) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-03@kbs.de to the CAB.Earliest start of the contract is 01.05.2023, provided that the contract and the required declarations or proofs are received by the CAB on 05.04.2023 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The deadline for receipt of accessions is 05.03.2025. In any case, the contracts end on 30.04.2025.

Opportunity closing date

05 March 2025

Value of contract

to be confirmed